drugset / Trial / NCT03918239
A Study to Determine the Bioavailability of Lanadelumab (SHP643) Administered Subcutaneously With the Prefilled Syringe and the Autoinjector in Healthy Adult Volunteer Participants.
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate bioavailability of lanadelumab (SHP643) following a single, 2 milliliter (mL) subcutaneous (SC) dose of 300 milligrams (mg) delivered by prefilled syringe (PFS) or auto injector (AI) in healthy adult participants.
Timeline
- Start
- 2019-05-14
- Primary completion
- 2019-11-13
- Completion
- 2019-11-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lanadelumab | Monoclonal antibody | 300 mg | Subcutaneous |
Indications
No indication recorded.